| Background and Objectives:At present, stroke has become the second leading cause of death following ischemic cardiovascular disease among patients with acute stroke accounted for about 80% of the all strokes. Ischemic stroke and hemorrhage stroke as the two types of stroke, which is currently still depending on the radiography as the major diagnostic criteria. However, the diagnostic effectiveness is still subject to a certain extent limits due to the different time, region, testing equipment, and personal circumstences. With the rise of molecular markers research, a large number of animal experiments and clinical studies of stroke was found that many molecular markers, however, are not yet used in clinical diagnosis. Heart type fatty acid type protein(H-FABP) is a cytoplasmic protein, widely present in cardic and neuronal cell bodies in vivo in brain after ischemic injury can be rapidly released into the blood as a potential molecular markers for cardiovascular and cerebrovascular disease research. In this study, serum H-FABP is detected and compared in patients with acute ischemic stroke(AIS) and intracerebral hemorrhage(ICH) to explore whether it has the potential differential diagnosis of stroke and the relationship among disease severity and etiologic subtypes of cerebral infarction. Methods:170 patients admitted with stroke within 12 hours of symptom onset to the People`s Hospital of Zhengzhou University and People`s Hospital of Huixian, from March 2015 and October 2015, were prospectively and consecutively enrolled in this study. Excluding patients older than 80 years and cranial MRI examination imperfect patients with acute cerebral infarction in 15 cases, 89 patients with AIS and 66 patients with ICH were finally enrolled to be analyzed the clinical data cllected by the experienced neurologists, and measured serum H-FABP by sandwich-type enzyme-linked immunosorbent assay(s ELISA). Statistical analysis:Statistically analysis was performed using the SPSS 17.0. The categorical data were compared between two groups by use of χ2 test or Fisher’s test. Continuous date were compared between two groups by use of Student’s t-test or Mann–Whitney U-test. Logistic regression analysis and nonparametric Spearman rank correlation test were used to identify the independent risk factors. P-value <0.05 was considered significant. Results:The difference of serum H-FABP for patients with AIS [132.14(81.63, 324.26) ng/L] was statistically insignificant compared to patients with ICH [171.35(102.86,382.65) ng/L](P > 0.05). There was no correlation between serum H-FABP and initial NIHSS(r=-0.11, P=0.307; r=0.094, P=0.451) in AIS and ICH patients; no difference was found among serum H-FABP, infraction volum and infraction location(P > 0.05). According to ASCO stardard, the etiological calssification of ischemic stroke, patients with cardiac cerebral infarction had a significantly higher serum H-FABP [263.65(126.32, 627.17) ng/L] than atherosclerotic cerebral infarction [115.36(82.14, 232.48) ng/L], small vascular infarction [123.06(74.95, 288.82) ng/L] and other causes of infarction [130.43(59.88, 268.10) ng/L], the difference was statistically significant(P < 0.05). Conclusion:Serum H-FABP can not be used to identify AIS and ICH, but may be a potiential predicted biomaker of cardiac cerebral infarction. |
PDF Full Text Request